These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795 [TBL] [Abstract][Full Text] [Related]
3. [NOAK in atrial fibrillation and renal failure]. St MMW Fortschr Med; 2016 Mar; 158(4):16. PubMed ID: 27119860 [No Abstract] [Full Text] [Related]
4. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601 [TBL] [Abstract][Full Text] [Related]
5. Time to reconsider dabigatran 110 mg in the USA. Hernandez I Am J Cardiovasc Drugs; 2015 Oct; 15(5):307-9. PubMed ID: 26068887 [TBL] [Abstract][Full Text] [Related]
6. [First NOAK with specific antidote]. Einecke D MMW Fortschr Med; 2015 Dec; 157(21-22):84. PubMed ID: 26960882 [No Abstract] [Full Text] [Related]
8. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Douketis JD; Healey JS; Brueckmann M; Eikelboom JW; Ezekowitz MD; Fraessdorf M; Noack H; Oldgren J; Reilly P; Spyropoulos AC; Wallentin L; Connolly SJ Thromb Haemost; 2015 Mar; 113(3):625-32. PubMed ID: 25472710 [TBL] [Abstract][Full Text] [Related]
9. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181 [TBL] [Abstract][Full Text] [Related]
10. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284 [TBL] [Abstract][Full Text] [Related]
11. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation. Efremidis M; Vlachos K; Letsas KP; Giannopoulos G; Lioni L; Georgopoulos S; Vadiaka M; Deftereos S; Sideris A J Electrocardiol; 2015; 48(5):840-4. PubMed ID: 26152604 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533 [TBL] [Abstract][Full Text] [Related]